Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET.
A live webcast will be available via Verrica's investor site and a replay will be posted and available for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
In the Apr 6 session, VRCA gained 9.32%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Full-year earnings | Positive | +4.7% | Reported strong 2025 revenue growth, YCANTH uptake, and extended cash runway. |
| Mar 05 | Earnings date set | Neutral | -2.4% | Announced timing and access details for Q4 and full-year 2025 results. |
| Feb 23 | Conference appearance | Neutral | -3.1% | Disclosed CEO presentation at TD Cowen health care conference with webcast access. |
| Feb 12 | Executive appointment | Positive | -2.3% | Named new Chief Commercial Officer to expand YCANTH commercialization and pipeline. |
| Feb 09 | Product launch abroad | Positive | +0.0% | Announced YCANTH launch in Japan through Torii Pharmaceutical for molluscum contagiosum. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates have often seen muted or negative next-day price moves, with only the strong earnings report aligning positively.
Over the last few months, VRCA has reported several milestones. On Mar 11, 2026, strong 2025 results and YCANTH growth drove a 4.68% gain. An earnings-date announcement on Mar 5, 2026 and a TD Cowen conference appearance on Feb 23, 2026 both saw modest declines. Management strengthened the commercial team with a new CCO on Feb 12, 2026, which also coincided with a small drop. The Japan YCANTH launch on Feb 9, 2026 produced a flat reaction. Today’s Needham conference news fits this pattern of event-focused, non-fundamental updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference.
25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026
Event details:
Date: Wednesday, April 15, 2026
Time: 3:00pm ET
Location: Virtual
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancer. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
